{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:40:46Z","timestamp":1783600846847,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["ID1059660"],"award-info":[{"award-number":["ID1059660"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Council","award":["MC_U105663142"],"award-info":[{"award-number":["MC_U105663142"]}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110159\/Z\/15\/Z"],"award-info":[{"award-number":["110159\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/I012826\/1"],"award-info":[{"award-number":["BB\/I012826\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["110158\/Z\/15\/Z"],"award-info":[{"award-number":["110158\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Methylglyoxal, a by-product of glycolysis and a precursor in the formation of advanced glycation end-products, is significantly elevated in the diabetic myocardium. Therefore, we sought to investigate the mitochondria-targeted methylglyoxal scavenger, MitoGamide, in an experimental model of spontaneous diabetic cardiomyopathy.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Male 6-week-old Akita or wild type mice received daily oral gavage of MitoGamide or vehicle for 10\u00a0weeks. Several morphological and systemic parameters were assessed, as well as cardiac function by echocardiography.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Akita mice were smaller in size than wild type counterparts in terms of body weight and tibial length. Akita mice exhibited elevated blood glucose and glycated haemoglobin. Total heart and individual ventricles were all smaller in Akita mice. None of the aforementioned parameters was impacted by MitoGamide treatment. Echocardiographic analysis confirmed that cardiac dimensions were smaller in Akita hearts. Diastolic dysfunction was evident in Akita mice, and notably, MitoGamide treatment preferentially improved several of these markers, including e\u2032\/a\u2032 ratio and E\/e\u2032 ratio.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that MitoGamide, a novel mitochondria-targeted approach, offers cardioprotection in experimental diabetes and therefore may offer therapeutic potential for the treatment of cardiomyopathy in patients with diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-019-06914-9","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T20:51:59Z","timestamp":1572036719000},"page":"669-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart"],"prefix":"10.1007","volume":"33","author":[{"given":"Mitchel","family":"Tate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin C.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles J.","family":"De Blasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runa","family":"Lindblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darnel","family":"Prakoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Deo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kiriazis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos D.","family":"Baeza-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart T.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda T.","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-0058","authenticated-orcid":false,"given":"Rebecca H.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"6914_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","volume":"128","author":"K Ogurtsova","year":"2017","unstructured":"Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40\u201350.","journal-title":"Diabetes Res Clin Pract"},{"key":"6914_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29\u201334.","journal-title":"Am J Cardiol"},{"key":"6914_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71:339\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"6914_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jacc.2003.11.024","volume":"43","author":"I Gustafsson","year":"2004","unstructured":"Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, K\u00f8ber L, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"6914_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1042\/CS20160491","volume":"131","author":"M Tate","year":"2017","unstructured":"Tate M, Grieve DJ, Ritchie RH. Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin Sci (Lond). 2017;131:897\u2013915.","journal-title":"Clin Sci (Lond)"},{"key":"6914_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","volume":"14","author":"DA Brown","year":"2017","unstructured":"Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017;14:238\u201350.","journal-title":"Nat Rev Cardiol"},{"key":"6914_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"H Bugger","year":"2014","unstructured":"Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660\u201371.","journal-title":"Diabetologia."},{"key":"6914_CR8","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.2337\/diabetes.54.11.3274","volume":"54","author":"PJ Beisswenger","year":"2005","unstructured":"Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes. 2005;54:3274\u201381.","journal-title":"Diabetes."},{"key":"6914_CR9","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1042\/BST0361045","volume":"36","author":"N Rabbani","year":"2008","unstructured":"Rabbani N, Thornalley PJ. Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochem Soc Trans. 2008;36:1045\u201350.","journal-title":"Biochem Soc Trans"},{"key":"6914_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.freeradbiomed.2013.11.025","volume":"67","author":"PBL Pun","year":"2014","unstructured":"Pun PBL, Logan A, Darley-Usmar V, Chacko B, Johnson MS, Huang GW, et al. A mitochondria-targeted mass spectrometry probe to detect glyoxals: implications for diabetes. Free Radic Biol Med. 2014;67:437\u201350.","journal-title":"Free Radic Biol Med"},{"key":"6914_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1159\/000487690","volume":"45","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Xiao H, Wu J, Zha L, Zhou M, Li Q, et al. Type I diabetic Akita mouse model is characterized by abnormal cardiac deformation during early stages of diabetic cardiomyopathy with speckle-tracking based strain imaging. Cell Physiol Biochem. 2018;45:1541\u201350.","journal-title":"Cell Physiol Biochem"},{"key":"6914_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.metabol.2005.08.017","volume":"55","author":"DS Fosmark","year":"2006","unstructured":"Fosmark DS, Torjesen PA, Kilhovd BK, Berg TJ, Sandvik L, Hanssen KF, et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism. 2006;55:232\u20136.","journal-title":"Metabolism."},{"key":"6914_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.biocel.2013.01.003","volume":"45","author":"C Antognelli","year":"2013","unstructured":"Antognelli C, Mezzasoma L, Fettucciari K, Talesa VN. A novel mechanism of methylglyoxal cytotoxicity in prostate cancer cells. Int J Biochem Cell Biol. 2013;45:836\u201344.","journal-title":"Int J Biochem Cell Biol"},{"key":"6914_CR14","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2337\/db15-0568","volume":"65","author":"B Vulesevic","year":"2016","unstructured":"Vulesevic B, McNeill B, Giacco F, Maeda K, Blackburn NJR, Brownlee M, et al. Methylglyoxal-induced endothelial cell loss and inflammation contribute to the development of diabetic cardiomyopathy. Diabetes. 2016;65:1699\u2013713.","journal-title":"Diabetes."},{"key":"6914_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejphar.2012.11.062","volume":"700","author":"B Hemmeryckx","year":"2013","unstructured":"Hemmeryckx B, Hoylaerts MF, Gallacher DJ, Rong Lu H, Himmelreich U, D\u2019hooge J, et al. Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice? Eur J Pharmacol. 2013;700:23\u201331.","journal-title":"Eur J Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s10557-019-06929-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000}}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-019-06914-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T23:17:31Z","timestamp":1603495051000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-019-06914-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6914"],"URL":"https:\/\/doi.org\/10.1007\/s10557-019-06914-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10557-019-06929-2","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"25 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article \u201cThe Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart\u201d","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2020","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article \ufffd\ufffd\ufffdThe Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart\ufffd\ufffd\ufffd","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All activities involving the use of animals for research were approved by the Alfred Medical Research Education Precinct (AMREP) Animal Ethics Committee and were conducted according to guidelines of the National Health and Medical Research Council of Australia for animal experimentation. For all experiments, we have included flow charts for the reporting of animal use and analysis in preclinical studies","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. However, MPM and RCH declare that they are inventors on a patent that includes MitoGamide: Mitochondria-targeted dicarbonyl sequestering compounds. Murphy, M. P.; Smith, R.A. J.; Hartley, R. C. WO 2015075200. A1.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}